Over a decade after launching one of the first treatments for idiopathic pulmonary fibrosis, Boehringer Ingelheim is rejuvenating its presence in the rare lung disease arena with a newly approved therapy. On October 7, the FDA approved JASCAYD, marking the first new IPF treatment in over ten years. The approval follows that of Boehringer’s OFEV and Roche’s ESBRIET, both of which were cleared in 2014 and currently dominate the US IPF market.
The new drug, nerandomilast, is a first-in-class, oral PDE4B inhibitor taken twice daily. Boehringer Ingelheim’s IPF treatment, JASCAYD, acts by inhibiting phosphodiesterase 4B, an enzyme abundantly present in the lungs that pla...
